Tag: ASCO
Polatuzumab Vedotin Demonstrates Clinical Efficacy Across a Range of Diffuse Large...
Polatuzumab vedotin (DCDS4501A), a novel, targeted anti-cancer agent being developed by Genentech/Roche, is a first-in-class anti-CD79b antibody-drug conjugate or ADC currently being investigated for...
Eric Rosenthal Reports | A Personal Remembrance of Two Giants of...
James F. Holland, MD, one of the pioneers of combination chemotherapy and cancer cooperative group research, died at the age of 92 on March...
Phase I Data of Enfortumab Vedotin in Metastatic Urothelial Cancer Supports...
Updated phase I data for enfortumab vedotin, also known as ASG-22ME or ASG-22CE , studied as monotherapy treatment for metastatic urothelial cancer (mUC) were...
XMT-1522 Trial in Progress Data Presented at ASCO
Data from a trials in progress abstract presented during the 2017 annual meeting of the American Society of Clinical Oncology (ASCO) confirmed the continued...
What to Expect at ASCO 2017
This year the premier oncology event - the annual meeting of the American Society of Clinical Oncology (ASCO), is just around the corner. The...
Clinical Phase I Data for ASG-15ME and Enfortumab Vedotin (ASG-22ME) Indicates...
Clinical data for ASG-15ME and Enfortumab vedotin, also known as ASG-22ME and ASG-22M6E, presented at the American Society of Clinical Oncology's (ASCO) 51st Annual Meeting held June...
AbbVie Demonstrates Progress in Oncology Research at ASCO 2016
Chemotherapy remains the standard of care in the treatment of many types of cancer. However, one of the problems with chemotherapeutics is that it...
ASCO 2016 Emphasizes Collective Wisdom: The Future of Patient-Centered Care and...
Only a few weeks until the start of the 2016 annual meeting of the American Society of Clinical Oncology (ASCO). This year’s ASCO, taking...
ADAPT Study Shows Promising Results in the Treatment of Patients with...
Results from the German phase II ADAPT study (WSG-ADAPT), showed that neoadjuvant ado-trastuzumab emtansine (T-DM1, Kadcyla®; Genentech/Roche) is effective in the treatment of HER2-positive,...
ASCO 2015: Advancing Antibody-drug Conjugates in Difficult-to-treat Cancers
With the 2015 Annual Meeting of the American Society of Clinical Oncology (ASCO), which was held in Chicago, Illinois, May 29 - June 2,...
